Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood cell ratios may flag dangerous pancreatitis early

NCT ID NCT07793734

Knowledge-focused Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 31, 2026 · Last updated Sep 02, 2026 · Updated 2 times

Summary

This study looks at whether routine blood test results can help predict which patients with acute pancreatitis will develop severe disease or die within 28 days. Researchers will track 109 adults admitted with acute pancreatitis and compare their blood cell ratios, such as neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio, against outcomes. The goal is to see if these inexpensive, widely available markers can serve as early warning signs for complications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If certain blood cell ratios reliably predict severe disease, doctors could identify high-risk patients earlier and tailor treatment more aggressively.
What could go wrong
This is an observational study, so it can only show associations, not cause and effect. The findings may not apply to all pancreatitis patients or lead to changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 109 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with acute pancreatitis admitted to El-Rahgi Liver Hospital, Assiut University, who meet the study eligibility criteria.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Diagnosis of acute pancreatitis based on at least two of the following: characteristic abdominal pain, serum amylase or lipase ≥ 3× upper limit of normal, or imaging consistent with acute pancreatitis * Admission within 72 hours of symptom onset Exclusion Criteria: * Chronic pancreatitis without an acute episode * Severe immunosuppression (neutropenia \< 500/mm³ or high-dose immunosuppressive therapy after solid organ transplantation) * Active non-pancreatic infection on admission requiring systemic antibiotics * Refusal to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute pancreatitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute pancreatitis pancreatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute pancreatitis Pancreatitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.